Santarus Inc (SNTS)

[kookiekook]

Target Price History

Current 1 Week Ago
High Target Price Estimate 5.50 8.00
Low Target Price Estimate 3.50 2.00
Mean Target Price Estimate 4.50 4.67
Standard Deviation 1.00 3.06
Date of Most Recent Estimate 10/17/10

Consensus EPS Estimates Trend

Qtr (09/10) Qtr (12/10) FY (12/10) FY (12/11)
Current Estimate -0.21 -0.03 -0.08 0.13
7 Days Ago -0.21 -0.03 -0.08 0.13
30 Days Ago -0.16 -0.01 -0.02 0.13
60 Days Ago -0.16 -0.01 -0.02 0.11
90 Days Ago -0.10 -0.02 0.02 0.13

Earnings Surprise

06/10 N/A N/A
EPS Estimate 0.04 N/A N/A
EPS Actual 0.10 N/A N/A
EPS Difference 0.06 N/A N/A
% EPS Surprise 150.00% N/A N/A

[Topgun21]

Sweet deal, we should do really well here!!

Looking forward to the fantastic DD from $heff and I-100.

Tim
SNTS

[nathanial]

Just got in at $3.25.

[Topgun21]

Anything is possible!! I think we punch through 200 Dma at 3.30.


Tim

[Dollar Bill]

Any chance the bears will make a run at this one like AVNR?

[Topgun21]

Have another order in at $3.23, no fills yet!!

This looks ready for a move up bigtime before Monday!

Tim
SNTS

[Topgun21]

Cycloset....

This is this month!

SWEET@!!

Tim
SNTS

[Topgun21]

Yes, I am now in for 12,500 shares as of today! This is due to $heff highlighting this extremely undervalued company!

Tim
SNTS

$heff board is Awesome!

[Topgun21]

Ok, I am in for 12,500 shares SNTS at $3.26!

Let's do it!

Tim

[Highyield33]

Also I noticed that $heff and his gang has started to accumulate SNTS. GLTA.

[Highyield33]

I like the look of the CFM going positive. I know SNTS will post a loss this qtr for the first time in a long time. But they have always beat estimates in the past. So the -.21 cent estimate loss could be alot better than expected. But with the commercially launch CYCLOSET in November 2010 this will get us to break out above the 200 dma. I am looking to ride this to $5 or better.

[john wayne]

I have my stop loss set at 3.04 and it didn't trigger today. Hopefully we've seen bottom

[Cryptics]

I jumped in beginning of the week....a little early but we'll see.

[Highyield33]

Huge fight today to shake some cheap shares loose. Going alot higher from here.

[deniseann]

SNTS Saw an add for Zegerid OTC, for heartburn relief, last night on the NBC Brian Williams 5:30cst World News.

also, a related link.

http://www.zegeridotc.com/zegeridotc/home/index.jspa?UTM_source=google&utm_medium=cpc&utm_term=zegerid&utm_campaign=Branded&gclid=CMuDqcCI8aQCFYVrKgod4XWl0Q

[deniseann]

SNTS Highest Return on Equity in the Pharmaceuticals Industry Detected in Shares of Cardiome Pharma (CRME, SNTS, BMY, LLY, AZN)

http://www.mysmartrend.com/news-briefs/news-watch/highest-return-equity-pharmaceuticals-industry-detected-shares-cardiome-pharm

[deniseann]

http://www.mysmartrend.com/news-briefs/technical-analysis/traders-gobbling-shares-santarus-shares-51-snts

[YoungShark]

Bullish accumulation going on giving good signs of a breakout above Sept 30th high of $3.34....unless we see a large market sell-off as big or bigger than this past Tuesday as the majority of stocks are susceptible to large market moves as such.

Chart Analysis

[deniseann]

SNTS
Market Capitalisation 191.0 mil
Latest Shares Outstanding 58.6 mil
339 Employees

[deniseann]

There are certainly people on the iHub that are more qualified than I to moderate this board, as i am not really in the profession of pharmaceuticals, but I am willing to take a shot at it.

I have had a holding in SNTS for a time and like the stock.

denise.

[deniseann]

Santarus also plans to initiate a Phase I clinical study in the first half of 2011 with its anti-VLA-1 antibody that the company expects to investigate for the treatment of rheumatoid arthritis.

This is forward looking, but currently, there are no good know cures for rheumatoid arthritis that I'm aware of.

[deniseann]

The company’s current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes. The company expects to commercially launch CYCLOSET in November 2010.

[deniseann]

SNTS This is a re-post excerpt from post 91 (this board) by FDA Plays moderator "cccpmd666". SNTS DD:

But very justified.

For ccc's graphics and excellent presentation, revisit POST 115.

I feel Santarus, Inc. is a long play at this point, but solid enough not to lose money for you, and if you're willing to wait it out, a very lucrative play. MHO

denise.



cccpmd666 Member Profile cccpmd666 Member Level Share Tuesday, April 20, 2010 3:28:55 PM
Re: None Post # of 115
SNTS DD:
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists, endocrinologists and other physicians. The company’s current commercial efforts are focused on ZEGERID® (omeprazole/sodium bicarbonate), which is indicated for the treatment of certain upper GI diseases and disorders, and on GLUMETZA® (metformin hydrochloride extended release tablets), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Santarus is also developing two late-stage lower GI product candidates, budesonide MMX® and rifamycin SV MMX®, for the U.S. market. Budesonide MMX is being investigated in a Phase III clinical program for the induction of remission of mild or moderate active ulcerative colitis. Santarus expects to begin Phase III clinical testing of rifamycin SV MMX in patients with travelers’ diarrhea in the second quarter of 2010.


Latest 10k http://ir.santarus.com/secfiling.cfm?filingID=950123-10-20667

ZEGERID® (omeprazole/sodium bicarbonate) is the Only Immediate-Release Oral proton pump inhibitor (PPI) providing continued acid control for patients with gastroesophagael reflux disease (GERD).
ZEGERID is indicated for:
•Short-term treatment (4-8 weeks) of active duodenal ulcer

•Short-term treatment (4-8 weeks) of active benign gastric ulcer
•Heartburn and other symptoms associated with GERD

•Short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed in endoscopy

•Maintenance of healing of erosive esophagitis (controlled studies do not extend beyond 12 months)

•Reduction of risk of upper GI bleeding in critically ill patients (powder for oral suspension only)

ZEGERID Powder for Oral Suspension 40 mg/1680 mg is the only FDA approved PPI for reduction of risk of upper GI bleeding in critically ill patients. Use beyond 14 days has not been evaluated.

[deniseann]

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by specialist physicians.

[surf1944]

3:26AM Santarus adds two novel biologic drug candidates to pipeline; acquires Covella Pharmaceuticals (SNTS) 2.53 : Co announces it has signed agreements with Pharming Group for exclusive North American Rights to RHUCIN. Co pays Pharming a $15 mln an upfront fee and an additional $5 mln milestone upon FDA acceptance. Also, co acquires worldwide rights for anti-VLA-1 antibody through acquisition of Covella Pharmaceuticals. Under the terms of the acquisition, co is paying a total in cash and stock of ~$1.8 mln in a combination of upfront consideration, assumption of Covella liabilities, and transaction expenses.

[surf1944]

UPDATE 2-Biotech firm Pharming gets U.S. partner

http://www.reuters.com/article/idCNLDE68C06B20100913?rpc=44

[pedromm]

IMPORTANT NEWS

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=54323202

This a 500 million market for this new product.

Good agreement

[surf1944]

Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET
Commercial Launch Anticipated in November 2010

Conference Call to Begin at 5:00 p.m. Eastern Time Today

http://finance.yahoo.com/news/Santarus-Licenses-Novel-Type-bw-3804668403.html?x=0&.v=1

[surf1944]

4:26AM Santarus extends maturity of $25 mln revolving line of credit from July 2011 to July 2013 (SNTS) 2.24

[surf1944]

Santarus Inc. Q2 2010 Earnings Call Transcript

http://seekingalpha.com/article/218155-santarus-inc-q2-2010-earnings-call-transcript?source=yahoo

[MetalHead]

took a position here today based on techs alone. Nothing to do with fundamentals.

[surf1944]

UPDATE 2-Santarus to stop promoting heartburn drug, cut jobs

http://www.reuters.com/article/idCNSGE65T0K520100630?rpc=44

[surf1944]

Santarus Announces Launch of Prescription ZEGERID Authorized Generic and Company Restructuring

http://finance.yahoo.com/news/Santarus-Announces-Launch-of-bw-2254255881.html?x=0&.v=1

[surf1944]

New Clinical Study Shows Patients With Type 2 Diabetes May Be Able to Tolerate Higher Doses of Metformin Using GLUMETZA

http://finance.yahoo.com/news/New-Clinical-Study-Shows-prnews-2905994211.html?x=0&.v=1

[kei]

just logged on again...looks like big buy order are coming at $2.68...looks like red all over today...ah....

[cccpmd666]

Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of rifamycin SV MMX® for the treatment of patients with travelers’ diarrhea.

“The Ministries of Health in Mexico and Guatemala have approved our clinical trial applications for the Phase III study with rifamycin SV MMX, and we are beginning to enroll patients at clinical sites in these countries,” said E. David Ballard, M.D., senior vice president, clinical research and medical affairs of Santarus. “Our plan for patient enrollment is to coincide with the peak summer travel season.”

He added, “Rifamycin SV has been used for more than 20 years in Europe in both intravenous and intramuscular dosage forms and has had a good safety profile. Rifamycin SV has also demonstrated a broad spectrum of in vitro activity targeted to the main enteropathogens that cause travelers’ diarrhea.”

The principal investigator for the Phase III clinical study is Herbert L. DuPont, M.D., Director of the Center for Infectious Diseases and Professor of Epidemiology at the University of Texas – Houston School of Public Health, Chief of Internal Medicine at St. Luke’s Hospital and Vice Chairman, Department of Medicine and Clinical Professor at the Baylor College of Medicine. Dr. DuPont is a recognized expert in public health and infectious diseases with an emphasis on travelers’ diarrhea.

In the Phase III clinical program, Santarus plans to undertake two international multicenter, randomized, double-blind studies, each with up to approximately 300 patients, to assess the efficacy and safety of rifamycin SV MMX 400 mg (2 times 200 mg) oral tablets taken twice daily (800 mg total daily dose) for three days versus placebo in the treatment of patients with travelers’ diarrhea. The primary endpoint of the Phase III clinical studies will be the time to last unformed stool (TLUS) and the studies will seek to demonstrate the superiority of rifamycin SV MMX to placebo.

Rifamycin SV MMX is a broad spectrum, semi-synthetic antibiotic with negligible systemic absorption, which is being developed for the treatment of patients with travelers’ diarrhea and potentially for other diseases that have an infectious component in the colon. Due to the negligible systemic absorption of rifamycin SV, the company believes that rifamycin SV MMX will offer an opportunity for limited side effects and will be less prone to the development of antibiotic-resistant strains of bacteria, a major concern with systemically delivered antibiotics.

[kei]

SNTS - poised to run today =^.^=

all in my wishful opinion!

good night!

[surf1944]

Santarus to Present at the Jefferies 2010 Global Life Sciences Conference

Press Release Source: Santarus, Inc. On Friday May 28, 2010, 4:00 am EDT
SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS - News), a specialty biopharmaceutical company, today announced that Gerald T. Proehl, president and chief executive officer, will make a presentation at the Jefferies 2010 Global Life Sciences Conference on Tuesday, June 8, 2010, at 11:00 a.m. Eastern time (8:00 a.m. Pacific time) at the Grand Hyatt in New York City.

A webcast of the presentation will be available during the event at http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.santarus.com&esheet=6308554&lan=en_US&anchor=www.santarus.com&index=1&md5=7c76aac1630f5b941e8d5627dc14aade and will be archived and available on the Web site for 14 days.

[kei]

running into fda decision???

[kei]

the fda decision is scheduled on or around june 4th.

i'm surprised that the pps doesn't go up for the anticipation and expectation towards the date.

lack of interest...?

[bolsheada]

We moving up 4th day in a row.

[surf1944]

Santarus Inc. Q1 2010 Earnings Call Transcript

http://seekingalpha.com/article/203634-santarus-inc-q1-2010-earnings-call-transcript?source=yahoo

[surf1944]

4:12PM Santarus beats by $0.06 (SNTS) 3.12 -0.22 : Reports Q1 (Mar) earnings of $0.05 per share, $0.06 better than the Thomson Reuters consensus of $(0.01); revenues rose 14.2% year/year to $39.7 mln vs the $39.0 mln consensus.

[cccpmd666]

Santarus Reports First Quarter 2010 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended March 31, 2010. Key financial results for the 2010 first quarter include:

* Net income of $3.3 million, or $0.05 per diluted share, increased 187% compared with net income of $1.2 million, or $0.02 per diluted share, in the prior year period
* Total revenues of $39.7 million, increased 14% compared with $34.8 million in the prior year period
* Product-related revenue of $37.8 million, increased 18% compared with $32.1 million in the prior year period
* Cash, cash equivalents and short-term investments of $90.8 million as of March 31, 2010

“While we are pleased with our solid top-line growth and achievement of our fifth consecutive quarter of profitability, we were very disappointed with the recent district court opinion in which the patents covering our ZEGERID® prescription products were found to be invalid, and we plan to file an appeal,” said Gerald T. Proehl, president and chief executive officer of Santarus. “We will continue to explore our options with ZEGERID while preparing for the launch of a generic version of ZEGERID. Regardless of the outcome on ZEGERID, we remain focused on positioning Santarus for future success by continuing to actively promote GLUMETZA®, working with our ZEGERID partners Merck Consumer Care, GlaxoSmithKline and Norgine, continuing the clinical development of budesonide MMX® and rifamycin SV MMX® and executing on our business development strategies.”

Business Highlights

Key first quarter and recent highlights include the following:

* Grew ZEGERID (omeprazole/sodium bicarbonate) net sales by 5% to $29.0 million, compared with net sales of $27.6 million in the first quarter of 2009. The company’s activities to modify or eliminate non-performing government and managed care contracts resulted in improved ZEGERID average selling prices as well as an anticipated decrease in prescription demand compared with the prior year period. ZEGERID total prescriptions were approximately 238,000 in the first quarter of 2010 versus approximately 294,000 in the first quarter of 2009.
* Increased promotion revenue for GLUMETZA (metformin HCl extended release tablets) by 95% to $8.8 million in the first quarter of 2010, compared with $4.5 million in the first quarter of 2009. GLUMETZA total prescriptions were approximately 79,000, up 28% over the first quarter of 2009.
* Completed enrollment in a second Phase III clinical study to evaluate budesonide MMX administered over eight weeks for the induction of remission of mild or moderate active ulcerative colitis. Enrollment in the first Phase III clinical study was completed in December 2009. Santarus expects to announce top-line results from these Phase III studies in July or August 2010.
* Announced the launch of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) by Schering-Plough HealthCare Products, Inc. (now also known as Merck Consumer Care), the global consumer products subsidiary of Merck & Co., Inc., under its licensing agreement with Santarus for the over-the-counter (OTC) heartburn market in North America. In the U.S., the OTC heartburn market is estimated at approximately $1.8 billion based on market research data and Santarus estimates.

First Quarter 2010 Financial Results

Total revenues for the first quarter of 2010 were $39.7 million, consisting of $37.8 million in product-related revenue and $1.7 million in royalty revenue and $0.2 million in other license revenue. Santarus reported $34.8 million in total revenues in the first quarter of 2009, including $32.1 million in product-related revenue and $2.7 million in other license revenue.

Santarus reported net income of $3.3 million, or $0.05 per diluted share, for the first quarter of 2010, compared with net income of $1.2 million, or $0.02 per diluted share, for the first quarter of 2009.

The cost of product sales was $1.6 million in the first quarter of 2010 and $1.9 million in the first quarter of 2009, or approximately 5% and 7% of net product sales, respectively. The decrease in cost of sales as a percentage of net product sales was primarily attributable to increased average selling prices.

Santarus reported license fees and royalties of $3.0 million in the first quarter of 2010, which consisted of royalties payable to the University of Missouri based on prescription ZEGERID and ZEGERID OTC™ net product sales, and amortization of the $12.0 million upfront fee paid to Depomed, Inc. in July 2008. License fees and royalties were $1.8 million in the first quarter of 2009, which consisted of royalties payable to the University of Missouri based on prescription ZEGERID net product sales and amortization of the same Depomed fee.

Research and development (R&D) expenses were $5.0 million in the first quarter of 2010, compared with $3.1 million in R&D expenses in the first quarter of 2009. The $1.9 million increase in R&D expense was primarily attributable to the ongoing budesonide MMX Phase III clinical program.

Selling, general and administrative expenses were $26.5 million for the first quarter of 2010, and $26.7 million for the first quarter of 2009.

As of March 31, 2010, Santarus had cash, cash equivalents and short-term investments of $90.8 million, compared with $93.9 million as of December 31, 2009. The decrease of $3.1 million resulted from changes in operating assets and liabilities offset in part by the company’s net income, adjusted for non-cash expenses, for the three months ended March 31, 2010.

Financial Outlook for 2010

Santarus’ 2010 financial results will be impacted substantially if a generic version of the ZEGERID prescription products is launched during 2010; therefore, Santarus has updated its financial outlook for 2010.

Santarus will continue to evaluate its options with ZEGERID while preparing a contingency plan in the event of the launch of a generic version of ZEGERID. Under its contingency plan, Santarus expects to cease promotion of ZEGERID, restructure and reduce its commercial organization and other impacted operations, and focus its product promotion on GLUMETZA. At the time of a generic launch, the company also plans to launch an authorized generic version of its ZEGERID prescription products.

Santarus is continuing to pursue the development of its pipeline products and expects R&D expenses for 2010 of up to $26 million, which includes estimated costs associated with the Phase III clinical programs for budesonide MMX and rifamycin SV MMX.

Santarus also may incur license fee expenses from two success-based milestones totaling $6 million in 2010. License fee expenses may include a $3 million sales milestone to Depomed, which is payable if annual net product sales of GLUMETZA exceed $50 million in 2010. In addition, assuming the achievement of the primary endpoints in each of the two Phase III studies for budesonide MMX with statistical significance and demonstrated adequate safety, license fees will include a $3 million development milestone payable to Cosmo Technologies Limited.

If generic versions of ZEGERID prescription products are launched, the company believes it can be profitable in 2010, excluding one-time charges associated with the generic launch and organizational restructuring costs.

Santarus is continuing to assess the impact of the recent U.S. healthcare reform legislation; however, at this time the company does not believe it will have a significant impact on its 2010 results.

Conference Call

Santarus has scheduled an investor conference call regarding this announcement at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) today, May 6, 2010. Individuals interested in participating in the call may do so by dialing 888-803-8275 for domestic callers, or 706-643-7736 for international callers. A telephone replay will be available for 48 hours following conclusion of the call by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers, and entering reservation code 72163066. The live conference call also will be available via the Internet by visiting the Investor Relations section of the company’s Web site at www.santarus.com and a recording of the call will be available on the company’s Web site for 14 days following the completion of the call.

[surf1944]

Santarus to Hold First Quarter 2010 Financial Results Conference Call on May 6

Press Release Source: Santarus, Inc. On Wednesday April 28, 2010, 4:00 am EDT
SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS - News), a specialty biopharmaceutical company, today announced that it will release first quarter 2010 financial results after market close on Thursday, May 6, 2010. Santarus management will host an investment-community conference call at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to discuss the financial results and provide a corporate update.

Individuals interested in participating in the conference call may do so by dialing [phone] for domestic callers, or [phone] for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company’s Web site at http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.santarus.com&esheet=6267777&lan=en_US&anchor=www.santarus.com&index=1&md5=50447a481a826ed4a9efad96e8458b5f.

A webcast replay will be available on the Santarus Web site for 14 days. A telephone replay will be available for 48 hours following the conclusion of the call by dialing [phone] for domestic callers, or [phone] for international callers, and entering reservation code 72163066.

[biznipianjr]

this is too cheap

[biznipianjr]

many new items will soon be here

[cccpmd666]

SNTS DD:
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists, endocrinologists and other physicians. The company’s current commercial efforts are focused on ZEGERID® (omeprazole/sodium bicarbonate), which is indicated for the treatment of certain upper GI diseases and disorders, and on GLUMETZA® (metformin hydrochloride extended release tablets), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Santarus is also developing two late-stage lower GI product candidates, budesonide MMX® and rifamycin SV MMX®, for the U.S. market. Budesonide MMX is being investigated in a Phase III clinical program for the induction of remission of mild or moderate active ulcerative colitis. Santarus expects to begin Phase III clinical testing of rifamycin SV MMX in patients with travelers’ diarrhea in the second quarter of 2010.


Latest 10k http://ir.santarus.com/secfiling.cfm?filingID=950123-10-20667

ZEGERID® (omeprazole/sodium bicarbonate) is the Only Immediate-Release Oral proton pump inhibitor (PPI) providing continued acid control for patients with gastroesophagael reflux disease (GERD).
ZEGERID is indicated for:
•Short-term treatment (4-8 weeks) of active duodenal ulcer

•Short-term treatment (4-8 weeks) of active benign gastric ulcer
•Heartburn and other symptoms associated with GERD

•Short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed in endoscopy

•Maintenance of healing of erosive esophagitis (controlled studies do not extend beyond 12 months)

•Reduction of risk of upper GI bleeding in critically ill patients (powder for oral suspension only)

ZEGERID Powder for Oral Suspension 40 mg/1680 mg is the only FDA approved PPI for reduction of risk of upper GI bleeding in critically ill patients. Use beyond 14 days has not been evaluated.

[surf1944]

Santarus SNTS Thomas Weisel Overweight

[reddymade]

SNTS: How low can this go?